CD4 and AIDS: Risk factors for azole-resistant oropharyngeal candidosis in AIDS patients, such as a low CD4 count, prolonged or multiple courses of therapy, intermittent therapy, a low daily azole dose (<100 mg/day), and a high total cumulative azole dose, have been identified [79,80,81,82].